The DOI matches its Crossref record; 103 of the 108 references it cites were found in a registry or an index.
ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
Open accessAbstract
Amyotrophic lateral sclerosis (ALS) is a devastating condition with an estimated mortality of 30,000 patients a year worldwide. The median reported survival time since onset ranges from 24 to 48 months. Riluzole is the only currently approved mildly efficacious treatment. Riluzole received marketing authorization in 1995 in the USA and in 1996 in Europe. In the years that followed, over 60 molecules have been investigated as a possible treatment for ALS. Despite significant research efforts, the overwhelming majority of human clinical trials (CTs) have failed to demonstrate clinical efficacy. In the past year, oral masitinib and intravenous edaravone have emerged as promising new therapeutics with claimed efficacy in CTs in ALS patients. Given their advanced phase of clinical development one may consider these drugs as the most likely near-term additions to the therapeutic arsenal available for patients with ALS. In terms of patient inclusion, CT with masitinib recruited a wider, more representative, less restrictive patient population in comparison to the only successful edaravone CT (edaravone eligibility criteria represents only 18% of masitinib study patients). The present manuscript reviews >50 CTs conducted in the last 20 years since riluzole was first approved. A special emphasis is put on the analysis of existing evidence in support of the clinical efficacy of edaravone and masitinib and the possible implications of an eventual marketing authorisation in the treatment of ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple small molecules with anti-inflammatory activity, including minocycline, masitinib, NP001, and celecoxib, have been tested for the treatment of ALS. Although most have failed, masitinib was found to be effective in the preceding clinical trials, and a Phase III clinical trial testing masitinib in ALS patients is ongoing.577”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [577]
Experimental — accuracy not yet measuredIn the citing paper
“Probiotics are considered to be dietary factors that can influence the human intestinal microbiota, which can affect the composition and structure of the intestinal flora; which, in turn, plays a role in protecting the intestinal epithelial barrier, inhibiting pathogen production, and regulating the immune system (3).”
From Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis (2023) · cites this paper as [3]
In the citing paper
“Through use of probiotics, the number of SCFA-producing microorganisms in the intestine can be increased (3).”
From Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis (2023) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
Bensimon, G., Lacomblez, L., & Meininger, V. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300901 · Cited by 2,239
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L., Bensimon, G., Meininger, V., Leigh, P. N., & Guillet, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91680-3 · Cited by 1,303
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Mitchell, J. D., & Moore, D. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447.pub3 · Cited by 1,123
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Jd, M., Lyon, M., & Moore, D. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447 · Cited by 910
Oxidative Stress in Neurodegenerative Diseases
Niedzielska, E., Smaga, I., Gawlik, M., Moniczewski, A., Stankowicz, P., Pera, J., & Filip, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9337-5 · Cited by 800
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682
Preclinical research: Make mouse studies work
Perrin, S. (2014) · Nature · doi:10.1038/507423a · Cited by 668
Flagged first, then by citations
5 of the 108 references couldn’t be matched to a known paper.
Research works printed but not linked: 5
- ARISLA (Fondazione Italiana de Ricerca Per La Sclerosi Laterale), 2014, ALS Clinical Trials List.
- Bradley, 1995, A phase I/II study of recombinant brain-derived neurotrophic in patients with ALS., Ann. Neurol., 38
- Rosenfeld, 2001, “Creatine monohydrate in amyotrophic lateral sclerosis: preliminary results,” in Proceedings of the, American Academy of Neurology Annual Meeting
- Teva, 2010, News Release.
- Tohgi, 1999, Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis., Ann. Neurol., 46, 129, 10.1002/1531-8249(199907)46:1129::AID-ANA213.0.CO;2-Y · DOI
Cited by
Sorted by citations
Items 301–400 of 451
Gong, F., Zhu, W. Z., Liao, W., Wang, M., Zheng, X., Wang, C., Liu, T., & Pan, W. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.873224 · Cited by 4
Dittlau, K. S., Chandrasekaran, A., Freude, K., & Bosch, L. V. D. (2024) · BIO-PROTOCOL · doi:10.21769/bioprotoc.4936 · Cited by 4
Castelli, L. M., Vasta, R., Allen, S. P., Waller, R., Chiò, A., Traynor, B. J., & Kirby, J. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.02.001 · Cited by 4
Otolaryngologist’s role in the diagnosis of amyotrophic lateral sclerosis
Costa, J. B., Pereira, D., Duarte, D., & Viana, M. (2021) · BMJ Case Reports · doi:10.1136/bcr-2020-234504 · Cited by 4
Monitoring ALS from speech articulation kinematics
Gómez‐Vilda, P., Londral, A. R. M., Gómez-Rodellar, A., Alonso, D. P., & Rodellar, V. (2018) · Neural Computing and Applications · doi:10.1007/s00521-018-3538-6 · Cited by 4
Mellinger, A. L., Griffith, E. H., & Bereman, M. S. (2020) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-020-02765-8 · Cited by 4
RNA as a source of biomarkers for amyotrophic lateral sclerosis
Kiaei, L., & Kiaei, M. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00738-z · Cited by 4
Povedano, M., Paipa, A., Barceló, M., Woodward, M. K., Ortega, S., Domínguez, R., Aragonés, M. E., Horrillo, R., Costa, M., & Páez, A. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05723-z · Cited by 4
Gálvez-Llompart, M., Zanni, R., García‐Domenech, R., & Gálvez, J. (2022) · Pharmaceuticals · doi:10.3390/ph15010094 · Cited by 4
Damme, J. V., Kuspinar, A., Johnston, W. S. W., O’Connell, C. M., Turnbull, J., Chum, M., Strachan, P. H., Luth, W., McCullum, S. A., Peters, N., et al. (2022) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2022.2029898 · Cited by 4
Reardon, T., Koller, G. M., Kortz, M. W., McCray, E., Wittenberg, B., & Hankinson, T. C. (2022) · Acta Neurologica Belgica · doi:10.1007/s13760-022-01889-1 · Cited by 4
A case report: Ayurvedic intervention in motor neuron disease contemplating Kaphavrutavata
Policepatil, B. V. (2022) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2022.100548 · Cited by 4
Yang, E. J., Lee, S. H., & Cai, M. (2022) · Mediators of Inflammation · doi:10.1155/2022/4754732 · Cited by 4
Firstenfeld, A. J., Servicio de Neurociencias, U. D. B. A., Listorti, J., Servicio de Neurociencias, U. D. B. A., Jalaff, N., Servicio de Neurociencias, U. D. B. A., Orozco, C., Servicio de Neurociencias, U. D. B. A., Gosdenovich, F. N., Servicio de Neurociencias, U. D. B. A., et al. (2023) · Journal of Medicine and Life · doi:10.25122/jml-2023-0459 · Cited by 4
Delivoria, D. C., & Σκρέτας, Γ. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1689-5_12 · Cited by 4
Борисович, Б. И. (2026) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041758 · Cited by 4
New developments in pre-clinical models of ALS to guide translation
Cock, L. D., Bercier, V., & Bosch, L. V. D. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.04.008 · Cited by 3
Inhibition of SOD1 trimerization is a novel drug target for ALS disease
Woo, T., Han, J., Kim, Y., Hwang, Y. J., Lee, M. G., Kang, S., Park, S., Ji, Y., Chung, Y., Baek, S., et al. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00483-8 · Cited by 3
Non-cell autonomous autophagy in amyotrophic lateral sclerosis: A new promising target?
Rosso, F., Magdalena, R., Torazza, C., Bacchetti, F., Milanese, M., Poletti, A., Bonanno, G., Cristofani, R., & Bonifacino, T. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107203 · Cited by 5
Sligar, C., Sluyter, R., & Ooi, L. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03764-9 · Cited by 3
Siddique, F., Imtiaz, S., Khizar, A., Noreen, S., Rasool, I. F. U., Kumar, P., Moreno, A., Khalid, W., & Esatbeyoglu, T. (2026) · Journal of Agriculture and Food Research · doi:10.1016/j.jafr.2026.102838 · Cited by 3
Animal Models of FUS-Proteinopathy: A Systematic Review
Rezvykh, A. P., Shteinberg, D. A., Bronovitsky, E. V., Ustyugov, A. A., & Funikov, S. Y. (2024) · Biochemistry (Moscow) · doi:10.1134/s0006297924140037 · Cited by 3
Martinez‐Thompson, J. M., & Staff, N. P. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197628638.003.0095 · Cited by 3
Sun, L., Zhao, W., Yan, M., Yang, B., Xiong, P., & Zhao, S. (2020) · Medicine · doi:10.1097/md.0000000000021933 · Cited by 3
Guo, N., Huang, W., Huang, J., Liu, Y., Zhu, K., & Gao, W. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1588968 · Cited by 4
Sharlow, E. R., Köseoğlu, M. M., Bloom, G. S., & Lazo, J. S. (2019) · Assay and Drug Development Technologies · doi:10.1089/adt.2019.914 · Cited by 3
Wheelchair Controlled by Eye Movement Using Raspberry Pi for ALS Patients
Buele, J., Aldás, J. V., Franklin Salazar, L., Soria, A., & Andaluz, V. H. (2019) · Advances in intelligent systems and computing · doi:10.1007/978-3-030-35740-5_9 · Cited by 3
Xu, Q., Cho, J., Chaouch, Z. B., & Lo, A. W. (2022) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2022.2136994 · Cited by 3
van Unnik, J. W. J., Nikolakopoulos, S., Eijkemans, M. J. C., Gonzalez‐Bermejo, J., Bruneteau, G., Morélot‐Panzini, C., van den Berg, L. H., Cudkowicz, M., McDermott, C. J., Similowski, T., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207306 · Cited by 3
Personalized Precision Immunotherapy for Amyotrophic Lateral Sclerosis (ALS)
Maharaj, D., Kaur, K., Saltese, A., & Gouvea, J. (2023) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2023048372 · Cited by 3
Tappenden, P., Hardiman, O. M., Kwon, S., Mon-Yee, M., Galvin, M., McDermott, C. J., & the ALS-CarE Study Group (2024) · PharmacoEconomics · doi:10.1007/s40273-024-01395-7 · Cited by 3
Young, C. A., Pinto, S., Großkreutz, J., Hardiman, O. M., Clawson, L., Cudkowicz, M., & Andrews, J. A. (2021) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2021.1920981 · Cited by 3
ALSUntangled 42: Elysium health’s “basis”
Bedlack, R., & The ALSUntangled Group (2017) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2017.1373978 · Cited by 3
Esophageal Disease in Older Patients
DeVault, K. R., & Achem, S. R. (2021) · Wiley eBooks · doi:10.1002/9781119599692.ch47 · Cited by 3
Basic Concepts and Emergent Disease Mechanisms of Amyotrophic Lateral Sclerosis
Sirozh, O., Sáez-Mas, A., Lafarga, V., & Fernández-Capetillo, Ó. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00266-2 · Cited by 3
Thumbadoo, K. M., Nementzik, L. R., Swanson, M., Dieriks, B. V., Dragunow, M., Faull, R. L. M., Curtis, M. A., Blair, I. P., Nicholson, G. A., Williams, K. L., et al. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107127 · Cited by 2
Sheikhpour, Z., Seyedalipour, B., Ataei, F., Baziyar, P., Akhlaghi, M., & Hosseinkhani, S. (2026) · Scientific Reports · doi:10.1038/s41598-026-42742-2 · Cited by 2
Safety evaluation of Tofersen in amyotrophic lateral sclerosis based on the FAERS database
Xiao, X., Hao, G., Wan, P., & Hou, W. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1843630 · Cited by 2
Sharma, T., Kumari, P., KUMAR, A., Ahmed, M., Ansari, A., Babu, Y. S., Brahma, M., Maruthi, M., Verma, A., Singh, J., et al. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146624 · Cited by 2
Tang, C., Zhu, L., Zhou, Q., Li, M.-H., Zhu, Y., Xu, Z., Lü, Y., & Xu, R. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.33461 · Cited by 2
Alginate Nanofiber Scaffolds for Amyotrophic Lateral Sclerosis
Maulding, D. M., Bielanin, J., Cole, P., Tian, Y., Saeeidi, M., Sharma, H. S., Sharma, A., & Tian, R. (2024) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-031-49744-5_9 · Cited by 2
Novel in vivo TDP-43 stress reporter models to accelerate drug development in ALS
Ferro, F., Wolf, C. R., Henstridge, C. M., & Iñesta-Vaquera, F. (2024) · Open Biology · doi:10.1098/rsob.240073 · Cited by 2
Headache types and characteristics in patients with Amyotrophic Lateral Sclerosis
Soliman, R., Fahmy, N. A., & Swelam, M. S. (2025) · The Journal of Headache and Pain · doi:10.1186/s10194-025-01987-4 · Cited by 2
Gorgich, E. A. C., Heidari, Z., Mahmoudzadeh‐Sagheb, H., Rustamzadeh, A., Shabani, A., Amirzadeh, A., & Ashtiani, B. H. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00593 · Cited by 2
Chong, P. G., Mazón, M., Cerdá-Alberich, L., Robles, M. B., Sierra, J. M. C., Vazquez-Costa, J. F., & Martí‐Bonmatí, L. (2025) · Neuroradiology · doi:10.1007/s00234-025-03732-9 · Cited by 2
Su, Z., Fang, M., Smolnikov, A., Vafaee, F., Dinger, M. E., & Oates, E. C. (2026) · Communications Biology · doi:10.1038/s42003-026-10189-w · Cited by 2
Delivoria, D. C., & Σκρέτας, Γ. (2020) · Springer protocols handbooks/Springer protocols · doi:10.1007/978-1-0716-0720-6_13 · Cited by 2
Management with antibiotics in Parkinson's disease
Bortolanza, M., Santos‐Lobato, B. L., Nascimento, G. C., & Bel, E. A. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815946-0.00029-6 · Cited by 2
Biomaterials in The Treatment of Amyotrophic Lateral Sclerosis
Nabizadeh, F. (2022) · Neurology Letters · doi:10.52547/nl.1.1.12 · Cited by 2
Zaki, S. D. B. A., & Lokin, J. K. (2023) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2023.00057 · Cited by 2
Dagan, B., Oren, O., Banerjee, V., Taube, R., & Papo, N. (2019) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25700 · Cited by 2
Imaging Biomarkers in Amyotrophic Lateral Sclerosis
Alberich, L. C., Vazquez-Costa, J. F., Ten‐Esteve, A., Mazón, M., & Martí‐Bonmatí, L. (2021) · Neuromethods · doi:10.1007/978-1-0716-1712-0_20 · Cited by 2
Wang, X., Kanda, H., Tsujino, T., Kogure, Y., Zhu, F., Yamamoto, S., Sakaguchi, T., Noguchi, K., & Dai, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052820 · Cited by 2
Surface glia predominantly contribute to the development of ALS/FTD in Drosophila modelPreprint
Snow, B. A., Stevenson, C. C., Kaur, J., Lee, S. G., Wei, Y., Miao, H., & Kim, W. J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.07.511246 · Cited by 2
Surface glia predominantly contribute to the development of ALS/FTD in Drosophila modelPreprint
Snow, B. A., Stevenson, C. C., Kaur, J., Lee, S. G., Wei, Y., Miao, H., & Kim, W. J. (2022) · Research Square · doi:10.21203/rs.3.rs-2259679/v1 · Cited by 2
Lee, I., & Simmons, Z. (2023) · Muscle & Nerve · doi:10.1002/mus.27828 · Cited by 2
Dysregulated expanded endocannabinoid system as therapeutic targets of amyotrophic lateral sclerosisPreprint
Ito, D., Iida, M., Iguchi, Y., Hashizume, A., Yamada, S., Kishimoto, Y., Komori, S., Shimamura, T., Takemoto, Y., Nakatochi, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.12.575341 · Cited by 2
Shijo, T., Suzuki, N., Warita, H., Kawauchi, Y., Mitsuzawa, S., Ikeda, K., Izumi, R., Ono, R., Ohno, A., Toyoshima, M., et al. (2022) · Neurology and Clinical Neuroscience · doi:10.1111/ncn3.12652 · Cited by 1
Huang, C., Qiu, L., Zhou, W., Shao, C., Wang, X., Zhang, Q., Chen, W., Xiong, M., Huang, M., Tang, M., et al. (2024) · Stem Cell Research · doi:10.1016/j.scr.2024.103604 · Cited by 1
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Thonhoff, J. R., Greene, E. P., & Appel, S. H. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_40 · Cited by 1
Khan, B., Iqbal, M. K., Khan, H. R., Kiyani, M. M., Bashir, S., & Li, S. (2025) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273347470250126185122 · Cited by 1
Chiò, A., Foucher, J., Gwathmey, K. G., & Ingre, C. (2025) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2025.2475893 · Cited by 1
Clift, A., Rowen, D., Knox, L., Griffiths, A. W., & McDermott, C. J. (2025) · Muscle & Nerve · doi:10.1002/mus.28437 · Cited by 1
Garrigos, D., Martínez-Morga, M., Pombero, A., García‐López, R., Pastor, D., Riquelme, D., Blanquer, M., Iniesta, F., Valdor, R., Geijo‐Barrientos, E., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02238-6 · Cited by 1
Jomaa, A. M., Khalid, H., Abozait, H. J., Mudassar, H., & Kaur, R. (2026) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_1101_25 · Cited by 1
Lysikova, E. A., Sitdikova, K., Makhambetova, A., Chaprov, K., Вячеславовна, Г. А., Kostin, A., Novikova, P. M., Lyundup, A., Askarova, S., Kukharsky, M. S., et al. (2026) · Cells · doi:10.3390/cells15171598 · Cited by 2
Deciphering the molecular logic of ALS using model organisms: “A family affair.”
Brent, J. R. (2017) · SOJ Neurology · doi:10.15226/2374-6858/4/1/00132 · Cited by 1
Serotonin and the 5-HT2B Receptor in Amyotrophic Lateral Sclerosis
Arnoux, A., & Dupuis, L. (2021) · The Receptors · doi:10.1007/978-3-030-55920-5_22 · Cited by 1
Antonescu, F., Butnariu, I., Adam, M., Antonescu-Ghelmez, D., & Tuță, S. (2022) · Neurology International · doi:10.3390/neurolint14030059 · Cited by 1
Ropert, B., Bannwarth, S., Genin, E. C., Vaillant-Beuchot, L., Lacas‐Gervais, S., Hounoum, B. M., Bernardin, A., Dinh, N., Mauri-Crouzet, A., D’Elia, M.-A., et al. (2024) · Brain · doi:10.1093/brain/awae348 · Cited by 1
Jankowiak, T., Cholewiński, M., Kryściak, K., Krok, E., Grycz, K., & Bączyk, M. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70375 · Cited by 1
Amyotrophic Lateral Sclerosis and Other TDP-43 Proteinopathies
Gómez-Deza, J., & Shaw, C. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00005-5 · Cited by 1
Keyless signature infrastructure solution for cloud attacks
Chandran, R., & Kumar, D. A. S. (2018) · International Journal of Engineering & Technology · doi:10.14419/ijet.v7i2.33.14822 · Cited by 1
Therapie der Amyotrophen Lateralsklerose
Holzer, M., Hermann, A., & Metelmann, M. (2019) · Nervenheilkunde · doi:10.1055/a-0883-6709 · Cited by 1
Respiratory complications of amyotrophic lateral sclerosis
Arroyo-Rojas, M. E., Torres-Fraga, M. G., Rodríguez-Reyes, Y. G., Guerrero‐Zúñiga, S., & Carrillo-Alduenda, J. L. (2019) · Revista de Fomento Social · doi:10.24875/rmn.19000074 · Cited by 1
Fit-for-purpose synthesis of dual leucine zipper kinase (DLK) inhibitor GNE-834
Xu, J. D., Carrera, D. E., Beaudry, D., Siu, M., Huestis, M. P., Liu, W., Angelaud, R., & Gosselin, F. (2020) · Tetrahedron Letters · doi:10.1016/j.tetlet.2020.152430 · Cited by 1
Improving clinical trial efficiency with machine learning models of disease progression
Beaulieu, D., Taylor, A. A., Pierce, D., Cuerdo, J., Schactman, M., Keymer, M., & Ennist, D. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00005-7 · Cited by 1
A Worsening Problem in ALS: Insurance Barriers Between Drug Approvals and Patient Access
Bedlack, R., Heitzman, D., & Shefner, J. M. (2024) · RRNMF Neuromuscular Journal · doi:10.17161/rrnmf.v5i1.21232 · Cited by 1
Exploring the use of synthetic placebo populations in ALS randomized clinical trialsPreprint
Bowles, H., Opie-Martina, S., Shojaiea, A., Libonatib, L., Iacoangelia, A., Khleifat, A. A., & Al-chalabi, A. (2022) · medRxiv · doi:10.1101/2022.12.09.22283281
Inhibiting toxicity of ALS-linked dipeptide repeat proteins by polystyrene sulfonate (PSS)Preprint
Bratek‐Skicki, A., Ahmed, J., Lindt, J. V., Jonckheere, K., Peeters, E., Heeren, K., Fakhri, F., Volkov, A., Hendrix, J., Batys, P., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.19.541518 · Cited by 1
Gong, X., Xie, Y., Wang, W., & Xu, T. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.17.682996 · Cited by 1
Rôle du peptide amyloïde dans les maladies neurodégénératives
Combes, M. (2018) · theses.fr (ABES) · doi:10.70675/a219ef4dzbca0z4272z8bf2z74080a1976e5 · Cited by 1
Existing and Emerging Therapies for Multiple Sclerosis
Chokhawala, H., Bir, S. C., & Minagar, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811709-5.00013-2
Protein Kinase Inhibitors for the Treatment of Multiple Sclerosis
Martı́nez, A., & Gil, C. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016070-00170
Newton, C. (2020) · Springer eBooks · doi:10.1007/978-3-030-30730-1_49
Pridmore, W. (2021) · RRNMF Neuromuscular Journal · doi:10.17161/rrnmf.v2i1.14822
Animal Models of ALS – Current and Future Perspectives
Déziel, R., Marriott, A. L., Kay, D. G., & Gill, D. A. (2021) · Wiley eBooks · doi:10.1002/9781119745532.ch8
Theme 05 - HUMAN CELL BIOLOGY AND PATHOLOGY (including iPSC studies)
(2021) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2021.1985791
Theme 07 - PRE-CLINICAL THERAPEUTIC STRATEGIES
(2021) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2021.1985793
Treatment and Management of Hereditary Neuropathies
Motley, W., Chaudry, V., & Lloyd, T. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-71317-7.00014-7
Tang, L., Dorst, J., Chen, L., Liu, X., Ma, Y., Günther, K., Michels, S., Müller, K., Freischmidt, A., Weishaupt, J. H., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-603164/v1
Tang, L., Dorst, J., Chen, L., Liu, X., Ma, Y., Günther, K., Michels, S., Müller, K., Freischmidt, A., Weishaupt, J. H., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-603164/v2
Prudlo, J., & Hermann, A. (2019) · Elsevier eBooks · doi:10.1016/b978-3-437-21882-8.00007-4
Improvement of amyotrophic lateral sclerosis symptoms using plant extracts
Obulesu, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-95762-5.00005-9
UNC13A Gene Brings New Hope for ALS Disease-Modifying Drugs
Chen, X., Chu, H., & Dong, Y. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00924-8
A função de proteínas associadas à Esclerose Lateral Amiotrófica em diferentes contextos celulares
Assoni, A. F. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.41.2022.tde-02082022-190632
Metadata
- Authors
- Petrov, D., Mansfield, C., Moussy, A., & Hermine, O.
- Affiliations
- AB Science (France) (FR)
- Hôpital Necker-Enfants Malades (FR)
- Corresponding author
- Hermine, Olivier
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2017-03-22
- Volume
- 9
- Pages
- 68-68
- ISSN
- 1663-4365 (ISSN-L)
- PMC
- PMC5360725
- OpenAlex
- W2597399186
- Cited by
- 451
- References
- 108
- Citations by year
- 2026: 28 · 2025: 41 · 2024: 45 · 2023: 46 · 2022: 65 · 2021: 63 · 2020: 53 · 2019: 52 · 2018: 50 · 2017: 8
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Aging Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-11-LABX-0051)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- amyotrophic lateral sclerosis, clinical trial failure, riluzole, edaravone, masitinib, drug development, clinical efficacy, patient selection criteria, drug approval, neurodegenerative disease therapeutics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
